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Abstract
The gastrointestinal (GI) tumour microenvironment is characterised by its 
unique colonisation with bacteria that are estimated to match the total number 
of cells in our body. It is becoming increasingly clear that the microbiome and its 
metabolites are important orchestrators of local and systemic immune responses, 
anticancer immunity and the host response to cancer therapy. Apart from their 
role as an energy source, metabolites have been shown to modulate inflammation, 
immune cell function and cancer cell survival. The polarisation of immune cell 
subsets by microbial metabolites towards either pro- or antitumorigenic functions 
strongly affects cancer progression and outcomes. In this chapter, we will discuss 
the link between microbial metabolites in the GI tumour microenvironment, 
anticancer immune responses and cancer progression.
Keywords: gastrointestinal tumour environment, host immune response, innate 
immunity, microbial metabolites, metabolism
1. Introduction
The GI tract is a complex ecosystem, populated by a large variety of bacteria, 
fungi and viruses that together form the intestinal microbiome. A surprising 
amount of local and systemic bodily functions are affected by the composition 
of the microbiome and its produced metabolites. This includes the generation of 
energy, metabolism of dietary components and synthesis of vitamins as well as 
regulation of immune responses, behaviour and mood. Perturbations of microbial 
populations, commonly referred to as dysbiosis, have been associated with a large 
number of diseases, such as inflammatory bowel disease [1], diabetes [2], obesity 
[3], autism [4], depression [5] and colorectal cancer [6, 7]. Understanding the 
reciprocal relationship between the microbiota and immunity has received great 
attention as it is becoming increasingly clear that inflammatory processes underlie 
many pathologies. The complexity of microbiome-immune interactions is stagger-
ing as not only the presence or absence of bacterial species shape immunity, but 
metabolites produced and modified by bacteria have a direct effect on the immune 
system’s ability to react to infectious and non-communicable diseases [8].
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Microbial metabolites, as the sum of products modified and synthesised by 
microbiota, can be a useful tool to understand microbiota-driven immune modula-
tion when analysis of bacterial lineages proves difficult. Diversity and abundance of 
microbial communities varies greatly amongst healthy individuals, whereas meta-
bolic pathways are conserved and stable [9, 10]. Therefore, assessing changes of 
metabolic pathways and how they affect immunity may provide crucial insights into 
the role of the GI microenvironment in health and disease. Microbial metabolites 
are commonly divided into three categories, (1) metabolites produced by bacteria, 
derived from host products; (2) metabolites modified by bacteria, derived from 
host products; and (3) metabolites synthesised by bacteria directly.
In the following sections, we will briefly describe GI cancers and components of 
the GI tract that shape the tumour microenvironment. Furthermore, we will discuss 
the evidence for connecting changes in the microbiome and its metabolites with 
carcinogenesis and the role of bacterial metabolites in shaping immunity and in 
particular anticancer immunity.
2. The GI cancer microenvironment
2.1 The gastrointestinal tract
The gastrointestinal tract starts at the mouth, extends to the anus and includes 
the oesophagus, stomach, small intestine, large intestine, liver and pancreas. Its 
main functions are primarily the disruption and digestion of food, absorption of 
nutrients and elimination of waste products. With the diverse functions of the GI 
tract, it is not unsurprising that it has a number of diverse environments which 
are contributed to by various types of immune cells and the multiple bacteria that 
reside in the GI tract.
Movement of food down the GI tract is facilitated by muscular contractions. 
Much of the tube that makes up the GI tract is muscle lined to enable this to occur, 
with sphincters at particular junctures to enable control of food passage. The muscle 
layers are coated by a mucous membrane which varies depending on the function of 
that section of the GI tract.
The epithelium that lines the GI tract can be broadly divided into three sub-
types, primarily based on their function. Squamous epithelium is found at the start 
(mouth and oesophagus) and end (anus) of the GI tract providing a protective cov-
ering. Secretory epithelium is found in the stomach. Absorptive epithelium is found 
in both the small and large intestines. The small intestine has numerous fingerlike 
projections, called villi, that increase the surface area to facilitate absorption of 
nutrients with interspersed crypts, or glands, which contain the stem cells that give 
rise to the epithelial cells. The absorptive epithelium of the large intestine is more 
closely packed with glands specialised for water absorption and mucus-secreting 
cells to lubricate the passage of faecal material down the GI tract.
The tube that forms the GI tract has a number of layers that lie between the 
outer muscular wall (the muscularis propria) and the innermost epithelium. The 
epithelium forms the innermost layer of the mucosa, which has two additional 
components, the lamina propria (composed of supportive connective tissue) and a 
thin layer of smooth muscle, the muscularis mucosae. Underneath the mucosa is the 
submucosa, which contains connective tissue, nerves and lymphatic and blood ves-
sels. The submucosa is surrounded by the outer muscularis propria, the muscle layer 
whose contractions facilitate passage of material down the GI tract. The supporting 
tissue surrounding the GI tract is called the adventitia or serosa and contains major 
nerves and blood vessels.
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The GI tract includes two large glands, the liver and pancreas. Both develop from 
the primitive foregut embryonically and have functions that contribute to digestion 
by generating digestive fluids. The liver produces bile, which can be stored and con-
centrated in the gallbladder. When lipids enter the duodenum, neuroendocrine cells 
of the duodenal mucosa are stimulated to release cholecystokinin-pancreozymin 
(CCK) causing contraction of the gallbladder releasing bile into the duodenum. 
Bile acids are emulsifying agents which aid in lipid digestion. Pancreatic secretions 
reach the duodenum via the pancreatic duct and contain a high content of alkaline 
bicarbonate ions which assist in neutralising the acidic fluid that has come from 
the stomach. The pancreas also produces a number of enzymes including trypsin, 
chymotrypsin, amylase, lipase and carboxypeptidases which are involved in the 
breakdown of proteins, carbohydrates and lipids.
2.2 Microbiota in the GI tract
Our lifestyle, including diet, exercise, childhood microbial exposure and the 
use of antibiotics strongly, influences the composition of our microbiota [9, 11–14]. 
Two phyla of bacteria dominate the human gut Bacteroidetes and Firmicutes. Over 
decades the ability to classify bacteria into their genus and species has evolved with 
technology resulting in numerous reclassifications. Bacteria can be additionally 
classified into subspecies on the basis of small but relevant differences within a 
species. Further classifications into strains or serovars, indicating variable immune 
antigens present on their surface, can be allocated outside nomenclature rules. This 
level of complexity demonstrates the purpose of studying microbial metabolites in 
the context of gut immunity, thereby avoiding the complexities of bacterial species, 
focusing instead on their metabolic output.
Epidemiological data initially made links between bacteria and cancer develop-
ment. However, identifying the role of bacteria in cancer development has been 
challenging due to the importance of host factors in cancer susceptibility combined 
with the ubiquitous nature of bacteria and the prolonged period between introduc-
tion of a bacterium and development of overt cancer [15]. This is further compli-
cated by environmental factors which are thought to play a much larger role than 
genetic makeup in determining the makeup of an individual’s microbiota [16].
While the knowledge of outcomes from bacterial interactions with human cells 
is growing, there is enormous potential for further discovery when accommodating 
other microbes that populate different levels of the gastrointestinal tract such as 
fungi and viruses [17].
2.3 Gastrointestinal cancers
Gastrointestinal (GI) cancers are as diverse as the environments of the GI tract 
and the various cell types found in the GI tract. Squamous cell carcinomas arise in 
the squamous epithelium of the oral cavity, oesophagus and anus. Those that arise 
in the oral cavity are considered head and neck cancers rather than GI cancers. 
Adenocarcinomas are cancers that arise from glandular epithelium and can arise 
in the oesophagus, stomach, small intestine, pancreas and large intestine. Other 
cancers that can arise from the GI tract include cholangiocarcinoma, with origin 
from bile duct cells; hepatocellular carcinoma (HCC), originating from hepatocytes 
(liver cells); gastrointestinal stromal tumours, originating from the interstitial 
cells of Cajal which have a role in the control of peristaltic contractions [18]; and 
neuroendocrine cancers which can arise from neuroendocrine cells throughout the 
GI tract. Multiple studies examining these GI cancers have demonstrated diverse 
molecular alterations within cancers that arise from the same cell type in the same 
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organ of the GI tract, highlighting the multitude of malignancies that can arise in 
the GI tract [19–27].
Chronic inflammation and infection are intimately associated with the devel-
opment of cancer, with 15% of global cancer cases in 2012 being attributed to a 
carcinogenic infection [28]. Examples from the GI tract include HCC with hepatitis 
B and C virus infections contributing to more than 70% of global HCC diagnoses 
in 2012 [28]. In gastric adenocarcinoma four molecular subtypes were described by 
The Cancer Genome Atlas (TCGA) in 2014, one is characterised by Epstein-Barr 
virus positivity and shows extreme DNA hypermethylation [29]. Helicobacter pylori 
(H. pylori) is considered a class I carcinogen by the World Health Organization due 
to the association of chronic infection with the development of gastric adenocar-
cinoma and mucosa-associated lymphoid tissue (MALT) lymphoma, a form of B 
cell lymphoma in the stomach [30, 31]. The risk of developing gastric cancer with 
H. pylori is dependent on the virulence factors of the strain causing infection, other 
environmental factors and host genetics [32–34].
In colorectal cancer studies, Fusobacterium subspecies were consistently identi-
fied as being differentially present in tumour samples; however, these findings 
are still limited by small sample sizes [35]. A study of the microbiome in a heredi-
tary form of CRC has implicated oncotoxins produced by co-colonisation with 
Bacteroides fragilis (B. fragilis) and Escherichia coli (E. coli) subspecies in mucosal 
biofilms. Further animal studies have revealed the bacterial synergy involved 
in carcinogenesis whereby the B. fragilis toxin increases expression of the pro-
inflammatory cytokine interleukin (IL)-17 enabling the oncotoxin-producing E. coli 
to invade the mucosa inducing DNA damage in epithelial cells [36].
In addition to bacteria and viruses being implicated in carcinogenesis, parasitic 
infections have also been implicated in cancer development in the GI tract, with 
liver fluke infection, particularly Opisthorchis viverrini, being associated with the 
development of cholangiocarcinoma [37].
2.4 Inflammation in the GI tract
Acute inflammation is an integral part of the host defence against pathogens 
and tissue damage and is also required for the initiation of beneficial antitumour 
immunity [38, 39]. In contrast, it is ongoing ‘smouldering’ inflammation that 
contributes to tumour development, progression, invasion and metastasis [40]. 
Low-grade inflammation affects the function of immune cells and promotes an 
immune-suppressive, tumour-promoting phenotype [41, 42]. This in turn is 
associated with reduced immune surveillance and clearance of tumour cells by the 
immune system.
Chronic inflammation can be induced through a variety of mechanisms, includ-
ing chronic infections [43], autoimmunity [44], metabolic disorders [45] and 
altered microbiota [46, 47]. In the GI tract in particular, the host immune system 
has to maintain a delicate balance, and pathogens and malignant cells need to be 
cleared, whereas normal flora has to be tolerated. Disruption of immune tolerance 
or dysbiosis may result in loss of epithelial barrier function and overstimulation of 
immune cells, leading to tissue damage and chronic inflammation.
Conditions associated with recurrent or chronic inflammation, such as inflam-
matory bowel disease (IBD), have been shown to contribute to the risk of develop-
ing small and large intestine cancers [48, 49]. Mechanistically, this has been related 
to increased stimulation of inflammation-promoting immune cells by altered 
microbiota [46]. As a result, pro-inflammatory cytokines and chemokines are 
secreted, attract further immune cells into the tissue and polarise them towards 
tumour-promoting functions [50–52]. Particularly the presence of pathogenic 
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T-cell subsets, induced by pro-inflammatory cytokines, has been shown to be a 
predictor of poor prognosis in colorectal cancer patients [53]. Chronic inflamma-
tion also contributes to the expansion of oncogenic bacteria thereby re-enforcing 
disease progression [54]. See Box 1 for an overview of the immune cell populations 
involved in intestinal antitumour immune responses.
3. Microbial metabolites that shape antitumour immunity
Metabolites produced or modified by bacteria significantly impact health 
and disease by acting locally on GI tract cells but can also have systemic effects 
by influencing the function and activation states of immune cells. The ‘metabo-
lome’ constitutes the sum of small molecules produced by a biological system 
and is a powerful approach to explore the current condition of that system [55]. 
Metabolomics refers to the analysis of metabolites using techniques, such as mass 
spectrometry, nuclear magnetic resonance analysis, high-performance liquid chro-
matography and gas chromatography coupled with mass spectrometry. Obtained 
peak patterns can be compared against spectral databases for identification of 
metabolites. Metabolomics can be combined with metagenomics, investigating 
the genetic material of the entire community, and metatranscriptomics, exploring 
which genes are expressed, to increase our understanding of microbiomes. The 
benefits, disadvantages and technical challenges of these omics techniques are 
reviewed extensively elsewhere [56–59].
Dendritic cells
DCs are innate immune cells that develop from 
myeloid precursors in the bone marrow. They are 
capable of detecting pathogens or tissue disturbances 
and initiate an inflammatory response. In the tumour 
microenvironment, they are thought to engulf dead 
tumour cells and debris and present fragments thereof to 
T cells, thus initiating anticancer immune responses.
Macrophages
Macrophages are antigen-presenting cells that arise from 
either circulating monocytes or embryonic progenitors 
that persist into adulthood, both giving rise to tissue-
specific macrophage populations that are capable of 
self-renewal [186, 187]. Macrophages serve important 
functions in immunity, cancer, metabolism and tissue 
repair. Macrophages play an important role in in the 
antitumour immune response but can also adopt a pro-
tumour phenotype in the tumour environment [188, 189].
Cytotoxic T cells (CD8+ T cells)
CTLs express the CD8 receptor and recognise antigens 
presented on the surface of antigen-presenting cells. 
Once primed by this encounter, CTLs are capable of 
recognising the same antigens and kill target cells 
expressing the antigen. Tumour-specific CTL responses 
are crucial for controlling tumour growth.
Helper T cells (CD4+ T cells)
Th cells express the CD4 receptor and support functions 
of innate and adaptive immune cells by secreting 
cytokines. Depending on the environment they 
encounter, Th cells develop into subsets with a wide range 
of functions [190].
Cytokines, such as IL-12, promote the development 
of Th1 cells, which are efficient at secreting IFN-γ 
and TNF-α, important cytokines for antitumour 
immunity. When naïve CD4+ T cells reside an 
environment high in IL-6 and TGF-β, they develop 
into Th17 cells, which promote autoimmunity and 
are a negative prognostic marker for colorectal 
cancer [49]. Th cells can develop into immune-
suppressive Tregs in the presence of TGF-β when 
expressing the transcription factor FOXP3.
Mucosa-activated invariant T cells (MAIT cells)
MAIT cells reside at mucosal surfaces in the lung 
and the intestine [163] and are widely distributed 
in tissue and the systemic blood circulation [164, 
165]. They have innate immune cell features but 
also express a semi-invariant T-cell receptor, 
which can recognise antigens presented on a 
monomorphic MHC class 1-related protein (MR1) 
expressed by antigen-presenting cells [166]. MAIT 
cells are first responders to a variety of infections 
caused by bacteria, fungi and viruses through 
detection of microbial B vitamin antigens.
Innate lymphoid cells (ILCs)
ILCs stem from the lymphoid lineage but have 
innate immune cell characteristics [109]. They are 
quick responders and contribute to elimination of 
pathogens and tissue homeostasis by producing 
a variety of cytokines. Based on their specific 
cytokine secretion, ILCs are grouped into different 
classes that resemble their T-cell counterparts, for 
example, group 3 ILCs (ILC3s) resemble Th17 cells 
and produce IL-17 and IL-22 [109].
Box 1. Overview of immune cell populations involved in intestinal antitumour immune responses.
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In the following sections, we will discuss the impact of microbial metabolites 
on immune cell function, focusing on how these metabolites shape the immune 
response. The anatomical components of the intestinal immune system including 
immune and epithelial cell populations and the mechanisms employed by these cell 
populations to discriminate between commensal and pathogenic bacteria have been 
reviewed extensively recently [60–66].
3.1 Metabolites produced by bacteria from dietary components
3.1.1 Short-chain fatty acids
Short-chain fatty acids (SCFAs) are 1–6 carbon volatile fatty acids which can 
either be in straight or branched chain conformation [67]. They are end products 
of fermentation of indigestible carbohydrates such as starch and fibre, by anaerobic 
microbiota in the caecum and large intestine [68]. SCFAs are the most abundant 
metabolite in the colon and consist almost entirely of acetate (C2), propionate (C3) 
and butyrate (C4) [69]. Acetate is the most common SCFA (60% of total SCFAs) in 
the colon and can also reach the systemic circulation after absorption from the GI 
tract. Propionate and butyrate make up roughly 20% of the SCFAs in faeces each 
[68, 70]. Propionate is mainly metabolised in the liver after draining into the portal 
vein after absorption from the gut mucosa, while butyrate is the preferred energy 
source of colonocytes and is digested locally [71].
SCFAs affect host physiology and pathology through a multitude of local and 
systemic mechanisms of action (Figure 1). In the GI tract, they act through binding 
to transmembrane G protein-coupled receptors (GPRs) and diffusion into epithelial 
and immune cells where they modify post-translational gene expression and func-
tion as energy source.
GPRs implicated in SCFA signalling are free fatty acid receptors GPR41, GPR43 
and GPR109a. The SCFAs acetate, propionate and butyrate have differing selectivity 
for these receptors with all three binding to GPR43, expressed on the GI epithelium 
and immune cells [72, 73]. Propionate and butyrate bind to GPR41, expressed by 
lamina propria cells in the large intestine, immune cells and cells of the peripheral 
nervous system [72]. Butyrate has also been found to ligate GPR109a expressed by 
large intestinal epithelium and certain subsets of immune cells [73].
Activation of the GPRs leads to changes in intracellular potassium concentra-
tions [K+], which directly activate intracellular danger-sensing molecular com-
plexes, called inflammasomes. Integral components of inflammasomes are Nod-like 
receptors, which are cytosolic pattern recognition receptors (PRRs). Particularly 
changes in the NLRP3 and NLRP6 inflammasomes (containing Nod-like receptors 
3 and 6, respectively) have been implicated in exacerbating intestinal inflammation 
[74–76]. Inflammasome complexes can be activated through a two-step process. 
The first signal is considered the ‘priming signal’, which induces nuclear factor 
(NF)-kB-mediated transcription of inflammasome components and pro-IL-1β and 
IL-18 in epithelial and immune cells [77]. The second signal leads to the assembly of 
the inflammasome complex and caspase-1-dependent processing of pro-IL-1β and 
IL-18 into their biologically active forms.
IL-1β and IL-18 are important signalling molecules for gut homeostasis and 
immune effector function. IL-1β can have pro- and anti-homeostatic functions, 
whereas IL-18 is generally regarded as a crucial cytokine for maintaining gut 
barrier integrity and a healthy microbiome composition. A reduction in IL-18 
secretion has been found to be associated with a shift in microbiota towards the 
expansion of Bacteroidetes, which promote colonic inflammation and carcinogen-
esis in mouse models [46, 76]. This aligns with findings that describe a decreased 
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expression of NLRP6 in gastric cancer, correlated with a reduced survival time 
in patients [78]. When the NLRP6 inflammasome was overexpressed, gastric 
cancer cell proliferation and development were inhibited, and migration and 
invasion of cancer cells were decreased. Furthermore, NLRP6 activity has been 
linked with intact epithelial barrier function and prevention of colorectal cancer 
Figure 1. 
Effects of the SCFA butyrate on epithelial and immune cell function. SCFAs are produced through 
fermentation of non-digestible fibre and starch by microbiota. (a) Cancer cells switch their metabolism to 
glycolysis and are less efficient at metabolising SCFAs such as butyrate, leading to accumulation of butyrate in 
the cell. Increased concentrations of butyrate inhibit HDAC activity and induce apoptosis, reduce proliferation 
and increase immunogenicity of cancer cells. (b) In healthy epithelial cells, butyrate is metabolised through 
oxidative phosphorylation and used as energy source by the cell. Butyrate also activates NLRP3 and NLRP6 
inflammasomes through binding to GPRs, resulting in secretion of cytokines IL-1β and IL-18. In turn, IL-18 
strengthens intestinal barrier integrity and promotes diversity of intestinal microbiota. (c) The effects of 
butyrate on immune cells in the lamina propria can be described as promoting the development and activity 
of anti-inflammatory populations, such as Tregs, while suppressing immune cell functions contributing to 
inflammation. Butyrate suppresses the maturation of DCs, limits their ability to prime CTLs and reduces the 
production of pro-inflammatory cytokines in DCs and macrophages. Together this reduces inflammation and 
the development of inflammatory Th subsets, such as Th17, which contribute to intestinal carcinogenesis.
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development [79]. Even though NLRP3 inflammasome activation has been 
shown to contribute to tumour-promoting inflammation and immune infiltrate 
in several ways [11, 80–83], many reports highlight the beneficial functions of 
the NLRP3 inflammasome in preventing intestinal cancer development. For 
example, activation of NLRP3 inflammasomes has been demonstrated to protect 
from intestinal carcinogenesis via IL-18-mediated epithelial repair [84] and sup-
pression of metastatic colon cancer growth via maturation of natural killer (NK) 
cells and stimulation of their tumoricidal activity [85]. The complex biology 
of intestinal inflammasome signalling and its role in tumorigenesis have been 
reviewed recently [74, 86]. It remains to be investigated how the often overlap-
ping and controversial findings regarding inflammasome functions orchestrate 
induction and resolution of inflammation.
SCFAs, particularly butyric acid and β-hydroxybutyrate, stimulate NLRP3 
and NLRP6 inflammasomes through binding to GPR43 and GPR109a, leading 
to increased production of IL-1β and IL-18 [87, 88]. Subsequently it was shown 
that dietary supplementation with sodium butyrate or increased consumption of 
dietary fibre protected mice against colitis [87] and colonic carcinogenesis [89] 
through production of IL-18 and promotion of gut homeostasis. Interestingly, even 
though activation of the NLRP3 inflammasome was mediated via activation of 
GPRs, stimulation of GPRs with synthetic agonists did not recapitulate these find-
ings, indicating that SCFAs must act on additional targets that influence cytokine 
secretion [90].
A prominent target of SCFAs is histone deacetylases (HDAC) and acetyltrans-
ferases (HAT), which regulate gene expression by allowing or preventing access of 
the transcription machinery to DNA. HDAC inhibitors have been used in cancer 
therapy for their ability to induce cancer cell death, reduce proliferation and 
increase immunogenicity of cancer cells as well as stimulate anticancer immune 
function [91–93]. Cancer cells utilise glucose as their primary energy source, and 
thus SCFAs, such as butyrate, accumulate and due to increased concentration 
inhibit HDAC activity [94]. In contrast, healthy cells are capable of metabolising 
butyrate into small molecules required for energy generation, thereby preventing 
accumulation of butyrate and HDAC inhibition [95, 96].
Interestingly, a similar mechanism may explain the diverging effects of butyrate 
on immune cell populations in the gut. In order to retain intestinal homeostasis, 
immune cells have to remain passive when challenged with host microbiota and 
food antigens yet remain responsive to fight pathogenic bacteria. This diversity of 
function is supported by SCFAs that induce a hypo-responsive state in immune cell 
populations, which are capable of promoting inflammation, such as macrophages, 
dendritic cells (DCs) and T cells [47], yet cells involved in containing inflammation 
are induced and expanded by SCFAs [97, 98].
DCs and macrophages are professional antigen-presenting cells, highly pro-
ficient at scanning the environment for invaders or tissue disturbances. Once 
detected, pathogens or abnormal cells are engulfed, processed and presented 
in small fragments to T helper (Th) cells. These cells, in turn, differentiate into 
populations of effector Th cells, directed by cytokines from DCs. Secretion of 
pro-inflammatory cytokines by DCs, such as IL-6, IL-12 and IL-23 in particular, 
supports the polarisation of Th cells towards effector and inflammatory subsets Th1 
and Th17, respectively. This is important for removal of pathogens but can be detri-
mental for tissue homeostasis if not regulated tightly. Th cells also facilitate the full 
activation and memory development of cytotoxic T cells (CTLs), which are able to 
kill antigen specifically and react swiftly in the case of a second encounter. SCFAs, 
butyrate and propionate, but not acetate, have been shown to reduce production of 
pro-inflammatory cytokines, such as IL-12 and IL-23, and chemokines in DCs and 
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also impair the maturation of DCs [90, 99, 100]. Changes in cytokine secretion are 
associated with impaired ability of DCs to prime CTLs [101], reduced polarisation 
of Th-cell subsets towards effector and inflammatory subsets and induction of 
regulatory T cells (Tregs) [102].
Regulatory T cells have an important role in control of inflammation. Tissue 
inflammation and autoimmunity are promoted if Tregs are not present or dys-
functional. In contrast to many other cancers where Tregs are thought to suppress 
effective antitumour immunity, GI cancer patients benefit from the presence of 
Tregs in the tumour microenvironment [103]. Tregs limit inflammatory processes, 
induce tolerance towards food and microbial antigens and promote stem cell 
renewal in the intestine through a variety of mechanisms. This includes production 
of anti-inflammatory cytokines, such as IL-10 and transforming growth factor beta 
(TGF-β)1, expression of inhibitory molecules and restriction of nutrients required 
by effector T cells, particularly Th1 and Th17 cells [64, 104–106].
Interestingly, due to the high rates of glycolysis in effector and pro-inflammatory 
cells, such as CTLs, Th1 and Th17 subsets, butyrate accumulates in these cells, 
leading to an inhibitory effect mediated by both HDAC inhibition and binding to 
GPR109a [90, 93, 102]. In contrast, anti-inflammatory cells, such as Tregs, which 
rely on oxidative phosphorylation can process butyrate for energy consumption, 
circumventing these effects [107]. It has been demonstrated comprehensively that 
SCFAs drive Treg development via HDAC inhibition and GPR activation in the 
intestine and periphery, thereby protecting mice against colonic inflammation, 
colitis and colorectal cancer [97, 98, 106, 108].
3.1.2 Indole derivatives
Indoles are aromatic heterocyclic compounds, produced by gut bacteria from 
the degradation of tryptophan via several enzymes [109]. Tryptophan is an essen-
tial amino acid, which cannot be produced by the host and is taken up in the diet. 
Dietary tryptophan can be metabolised by microbiota and host cells to indole 
derivatives that have important immune modulatory functions in the gut [110]. 
Indole derivatives, such as kynurenines, are ligands for the aryl hydrocarbon recep-
tor (AHR), an intracellular ligand-activated transcription factor with important 
roles in detecting environmental changes and alerting cells to them. Microbial AHR 
ligands are thought to play an important role in maintaining intestinal homeostasis 
and limiting inflammation [111]. The importance of AHR signalling has been 
demonstrated in AHR−/− mice where clearance of pathogenic bacteria was impaired 
while intestinal inflammation was elevated and associated with an increased risk of 
developing colitis [112–114].
Mechanistically, bacterial AHR ligands have been shown to induce the produc-
tion of IL-22 in innate lymphoid cells (ILCs), which promotes diversity of gut 
microbiota and protects mucosal barrier functions [115, 116]. ILCs stem from the 
lymphoid lineage but have innate immune cell characteristics [117]. They are quick 
responders and contribute to elimination of pathogens and tissue homeostasis 
by producing a variety of cytokines. Based on their specific cytokine secretion, 
ILCs are grouped into different classes that resemble their T-cell counterparts, for 
example, group 3 ILCs (ILC3s) resemble Th17 cells and produce IL-17 and IL-22 
[117]. Even though production of IL-22 by ILC3s is vital for mucosal homeostasis, 
elevated levels of ILC3s and increased production of IL-17 have been associated 
with IBD pathology [118, 119]. Furthermore, it has been found that IL-22 contrib-
utes to tumorigenesis in the colon when elevated chronically. This was mediated 
via an inflammasome-dependent reduction of IL-22 binding protein and chronic 
elevated IL-22 levels [50, 51].
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Genetic induction of constitutively active AHR signalling in mouse models has 
been found to be associated with stomach and liver cancer development [120, 121], 
whereas the absence of AHR in AHR−/− mice protected from prostate cancer [122]. 
As AHR is crucially involved in early development, maintenance of stem cells and 
cell differentiation, it is difficult to discern if stable genetic induction or ablation of 
these signalling pathways may promote carcinogenesis directly or through distur-
bances in early development.
3.1.3 Polyamines
Polyamines are small polycationic molecules, derived either from the diet or 
synthesised by gut bacteria or host cells [123]. While they are found in almost all 
living cells, the method of production in mammalian and bacterial cells differs. 
Intestinal bacteria use inducible or constitutive forms of amino acid decarboxylase 
enzymes in order to produce polyamines with arginine as a precursor. Mammalian 
synthesis involves a series of steps to convert arginine to polyamines, with ornithine 
decarboxylase being the rate-limiting enzyme. Putrescine, spermidine and sperm-
ine are the major polyamines secreted by both the gut microbiota and mammalian 
cells and have important immune modulatory functions [124].
Along with other polyamines, spermine directly regulates cells in the innate 
arm of the immune system and has an anti-inflammatory effect. Spermine inhibits 
lipopolysaccharide-induced expression of pro-inflammatory cytokines in mono-
cytes and macrophages [125]. In macrophages, spermine is able to increase the 
expression of IL-10 and suppress production of inflammatory cytokines such as 
IFN-γ [126]. These functions were shown to have anti-inflammatory and protective 
effects in animal models of local and systemic inflammation [127].
Conversely, spermine inhibits the activation of the NLRP6 inflammasome and 
reduces the amount of IL-1β and IL-18 released. This is counteracted by taurine, 
another microbial metabolite, which is discussed below. The inhibitory effect of 
spermine on NLRP6 activity may be counteracted by the role polyamines play in 
maintenance of the gut epithelial lining. Many studies have found that intestinal 
mucosal repair is associated with an increase in levels of spermine, spermidine and 
putrescine [128]. Furthermore, when the synthesis of polyamines is blocked, migra-
tion and proliferation of intestinal epithelial cells to the site of injury as well as in 
regular turnover of mucosal cells are significantly reduced. Polyamines promote the 
transcription of E-cadherin, which is important for the formation of tight junctions. 
In this regard, they play a role in stabilising the gut epithelium, so it is able to act as 
a barrier between the external and internal environment [128].
3.2 Metabolites modified by bacteria, derived from host products
3.2.1 Bile acids and derivatives
Bile acids are physiological surfactants, produced in the liver and secreted into the 
duodenum or stored in the gall bladder. Bile acid molecules contain a hydrophobic 
hemisphere and a hydrophilic one, enabling them to associate around dietary fats and 
fat-soluble vitamins into micelles [129]. This promotes the breakdown and absorption 
of these molecules in the hydrophilic environment of the GI tract [130]. Approximately 
95% of bile acids are reabsorbed via active transport by the apical sodium-dependent 
bile acid transporter in the ileum of the small intestine [131]. Microbial bile salt hydro-
lases catalyse the hydrolysis of amide bond linkage in bile acids, releasing an uncon-
jugated bile acid. The de-conjugation of bile acids causes the release of glycine and 
taurine, which can then be used for further metabolism and growth.
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Bile acids modulate innate immune cell function by inhibiting NF-kB activity, 
resulting in reduced production of pro-inflammatory cytokines and molecules 
(TNF-α, IL-1β, IL-6, IL-12, cyclooxygenase-1 and cyclooxygenase-2, and induc-
ible nitric oxide synthase) in stimulated monocytes, macrophages, DCs and 
intestinal epithelial cells [132–135]. In human macrophages, administration of 
bile acids leads to increased production of IL-10 and a decrease in phagocytosis 
[136]. The reduction in pro-inflammatory cytokines combined with the increase 
in anti-inflammatory cytokine production induces the development, recruitment 
and expansion of Tregs in the colon. Together, the properties of bile acids improve 
barrier integrity and outcomes in mouse models of experimental colitis, which lead 
to the development of inflammatory bowel disease and colorectal cancer [133]. The 
effects occur via bile acid-mediated activation of the farnesoid X receptor (FXR), 
a ligand-activated nuclear receptor, and the G protein-coupled bile acid receptor 1 
(GPBAR1). These receptors also play a crucial role in bile acid-induced inhibition of 
the NLRP3 inflammasome, which is associated with reduced levels of secreted IL-1β 
and IL-18 [137, 138].
In contrast to primary bile acids, the bile acid-derivative taurine stimulates 
NLRP6 inflammasome activity, leading to increased production of IL-18 [139]. 
Levy et al. found high taurine and associated IL-18 concentrations maintained and 
restored functional microbiota typically present in healthy flora.
3.3 Metabolites synthesised by bacteria directly
Microbiota are able to synthesise metabolites that are either unique to prokary-
otic organisms, such as capsule polysaccharides and certain vitamins, or that can 
also be produced by host cells, for example, adenosine triphosphate (ATP).
3.3.1 ATP
In addition to its role as universal energy source, ATP is an important signal-
ling molecule that directly impacts immune cell function when released into the 
extracellular space. ATP is not only produced by living organisms but has been 
found to be secreted by a variety of commensal and pathogenic bacteria [140, 141]. 
Generally, increased levels of ATP are produced and secreted by host cells under 
inflammatory stress conditions and injury, often associated with inflammatory cell 
death [142]. Furthermore, the tumour microenvironment has high concentrations 
of extracellular ATP, at least partly induced by hypoxia, an activator of ATP secre-
tion, and necrotic cell death [143, 144]. The chronic presence of ATP in the tumour 
microenvironment supports cancer cell proliferation, survival and metastasis as 
reviewed elsewhere [144]. In the immune context, most of the actions of ATP have 
been described to be pro-inflammatory; however, its hydrolysis product adenosine 
has immune-suppressive functions.
Host-, tumour- and microbial-derived ATP binds to purinergic-type receptor 
P2, while adenosine, the downstream product of hydrolysed ATP, binds to P1 recep-
tors [144]. Purinergic P2 receptors are expressed highly by immune cells, and ATP 
exerts most of its pro-inflammatory effects through binding to P2X(1–7) ion chan-
nels and P2Y(1, 4, 6, 11–14) metabotropic purinergic receptors [145]. Activation 
of purinergic receptor P2X7 by ATP increases intracellular potassium and calcium 
concentrations [146]. Together with a priming signal, ATP is an important inducer 
of NLRP3 inflammasome activity [147]. As discussed previously, activation of the 
NLRP3 inflammasome and the subsequent secretion of IL-1β and IL-18 have impor-
tant roles in shaping the magnitude of inflammatory responses, gut homeostasis 
and barrier function and have a controversial role in tumour progression [86].
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Besides its role as inflammasome activator, ATP modulates migration of innate 
and adaptive immune cell subsets [148]. After release of ATP into the extracel-
lular space, innate immune cells such as monocytes, mature DCs, neutrophils, 
macrophages and microglia are mobilised via activation of P2X and P2Y receptors 
and migrate to the source of the high ATP concentration. This migratory response 
is further amplified through autocrine activation of pannexin 1 channels in the 
membrane of innate immune cells [149–153]. Interestingly, ATP has been shown 
to affect migration of CD4+ T-cell subsets differently, depending on their function 
and activation status. While activated CD4+ T cells respond to high ATP concen-
trations and stimulation of P2X7 and P2X4 receptors with induction of apoptosis, 
immune-suppressive Tregs increase proliferation and migration via their P2Y2 
receptor [154].
In the context of intestinal inflammation and carcinogenesis, ATP drives the 
polarisation of CD4+ T cells towards IL-17-producing CD4+ T cells, associated with a 
higher susceptibility to develop colitis and exacerbation of existing colitis in experi-
mental mouse models [155, 156]. A Th17 signature in colorectal cancer patients is 
associated with disease progression and worse outcomes [53]. Polymorphism of 
the ATP-converting enzyme CD39 (hydrolysis of ATP to adenosine diphosphate 
(ADP)) in IBD patients and increased expression of P2X7 receptors in the inflamed 
epithelium of Crohn’s patients have been found, suggesting another role of ATP in 
disease pathology [156, 157].
ATP is hydrolysed by CD39 and CD73 to adenosine, which have been widely 
investigated and reviewed for their immune-suppressive functions in the tumour 
environment [144, 151, 152, 158]. Therapeutic inhibition of ATP and adenosine 
receptors as well as targeting of CD39 and CD73, alone and in combination with 
traditional chemotherapy, has shown great promise to prevent tumour growth by 
overturning adenosine-induced immune suppression [159–163]. However, recent 
evidence demonstrates that extracellular ATP is required for the formation of long-
term, antigen-specific CTL responses, which are crucial for immunological memory 
[164]. It remains to be determined if therapeutic targeting of purinergic receptors 
and conversion enzymes affects development of immunological memory in cancer, 
which is desirable to prevent cancer occurrence.
3.3.2 Vitamins
Humans lack the ability to produce most essential vitamins and rely on 
vitamins to be supplied with the diet and produced by gut bacteria. Microbiota 
are able to synthesise vitamin K and a large number of B vitamins, such as folate 
(vitamin B9), riboflavin (vitamin B2), pyridoxine (vitamin B6), cobalamin 
(vitamin B12) and methionine [165]. B vitamins have achieved great attention 
for their cancer-preventing properties, with folate being the most investigated 
B vitamin in the cancer context [166]. The cancer-preventing mechanisms have 
been attributed to the role of B vitamins as cofactors in metabolic processes 
related to energy generation and gene regulation [166, 167]. Folate (B9) and 
pyridoxine (B6) have also been found to modulate intestinal immunity by 
increasing CD4+ T-cell proliferation, trafficking and survival of Treg subsets and 
NK cell cytotoxicity [168–170].
Interestingly, bacteria that synthesise vitamins B2 and B9 are recognised by 
mucosa-activated invariant T (MAIT) cells. MAIT cells reside at mucosal surfaces 
in the lung and the intestine [171] and are also widely distributed in tissue and 
the systemic blood circulation [172, 173]. They have innate immune cell features 
but also express a semi-invariant T-cell receptor, which can recognise antigens 
presented on a monomorphic MHC class 1-related protein (MR1) expressed by 
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antigen-presenting cells [174]. MAIT cells are first responders to a variety of 
infections caused by bacteria, fungi and viruses through detection of microbial B 
vitamin antigens.
Upon activation, MAIT cells are able to proliferate and produce cytotoxic 
molecules, capable of destroying infected cells displaying microbial B vitamin 
antigens on their MR1 protein [175–177]. Furthermore, MAIT cells produce immune 
modulatory cytokines, including IFN-γ, IL-2, IL-17, IL-10 and TNF-α [178]. While 
IFN-γ production is highly desirable to promote antitumour immunity, an IL-17 
signature has been found to be associated with worse outcomes in CRC patients 
[53]. Numbers of MAIT cells decrease in the peripheral circulation but accumulate 
in intestinal tumours [179, 180]. Several groups report a diminished ability of 
tumour-infiltrating MAIT cells to produce IFN-γ combined with increased secre-
tion of IL-17 [180, 181]. Even though it appears that MAIT cells may develop a 
tumour-promoting phenotype in the tumour microenvironment and thus contrib-
ute to cancer progression, further studies are needed to elucidate the role of these 
recently discovered cells.
It is tempting to speculate that MAIT cells may impact intestinal cancer devel-
opment and progression through recognition of B vitamin antigens produced by 
dysbiotic and carcinogenic bacteria. Since MAIT cells can be activated or inhibited 
depending on the B vitamin antigen presented on MR1 proteins, MAIT cells have 
been suggested as attractive targets for cancer immunotherapy [182]. This is in part 
related to their potential to be targeted in combination with chemotherapy, due 
the expression of drug resistance proteins that allows their survival and activation 
during and post-chemotherapy [172].
3.3.3 Bacterial polysaccharides
Commensal bacteria contribute to intestinal homeostasis through production 
of capsular polysaccharides. Polysaccharide A (PSA), the most studied bacterial 
polysaccharide, is produced by B. fragilis and plays an important role in regulating 
intestinal inflammation. Exogenous administration or bacterial production of PSA 
can prevent the development of experimental colitis by activating Treg and inhibit-
ing Th17 responses [183–185]. This is mediated by PSA binding to PRRs expressed 
by DCs, which in turn secrete IL-10 that promotes the development and activation 
of Tregs. Furthermore, PSA influences the polarisation of Th subsets towards IFN-
γ-producing Th cells, an important effector population for anticancer immunity. B. 
fragilis are not the only commensals that regulate inflammation; many other strains, 
for example, a large number of Clostridium strains [186], have been shown to have 
anti-inflammatory functions. This highlights the fact that the sum of commensals 
and their metabolites, rather than a defined strain or metabolite, shapes the func-
tionality of the immune system by impacting the polarisation of immune subsets, 
crucial for clearance of diseases.
4. Conclusions
The link between microbiome disturbances and the development of inflam-
matory diseases highlights the importance of studying the effects of microbes and 
their metabolites on immune cell function. Deciphering the effects of microbial 
metabolites on the immune system in a highly dynamic organ system, such as the 
GI tract, is inherently difficult. The actions of individual metabolites need to be 
considered before the complex interplay of microbes, metabolites and cellular 
components, such as epithelial and immune cells can be investigated. The GI 
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tumour microenvironment is unique in that immunological tolerance is required to 
maintain a healthy intestinal environment, including maintenance of the “normal” 
microbiome, yet the presence of regulatory immune cells may impede antitumour 
immune responses and promote carcinogenesis.
There is increasing evidence from preclinical mouse model systems and human 
studies that GI tract microbiota, such as B. fragilis, Bifidobacterium, Faecalibacterium 
prausnitzii and Akkermansia muciniphila, can directly influence response to treat-
ment including immunotherapies and survival in some malignancies [187–193]. 
This effect is potentially mediated by bacteria stimulating activation of innate 
immune cells and downstream polarisation of Th-cell subsets towards Th1 cells 
[194]. The species and diversity of bacterium identified as influencing treatment 
response and survival vary, likely reflecting the complexity of the interactions 
involved, the diverse malignancies and populations within which those malignan-
cies had arisen, and the number of bacterial species that have immunomodulatory 
effects mediated through the GI tract.
The influence of infections on initiation and promotion of cancer has been long 
recognised, but our understanding of the complex network of interactions between 
the host, the microbiome, the genetics of both the host and microbiome and the 
metabolome remains superficial. These interactions are not static, which, with the 
diversity of the GI tract environment, add to the challenge of deciphering what 
microbial species may be influencing the immune response in a tumour-promoting 
or tumour-suppressive manner. The complexity of microbial species and indeed 
the complexity of immune cells and their function mean that practically assaying 
and identifying individual species of bacteria, or subsets of immune cells, clinically 
in a prognostic or predictive sense is challenging. The more readily measureable 
microbial metabolome may provide a more clinically accessible read-out of this 
interaction. The wide-ranging impact that products of microbial metabolism have 
on immune cell function and polarity and therefore anticancer immunity has 
been underappreciated to this point. A greater understanding of how microbial 
metabolites influence the GI tumour microenvironment has the potential to expand 
therapeutic options and improve survival of patients with GI cancers.
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